Proteostasis Therapeutics

Kineta, Inc. is a clinical-stage biotechnology company, which develops immunotherapies for cancer patients. Its immuno-oncology focused platform aims at developing fully human antibodies to address the major mechanisms of cancer immune resistance. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Seattle, WA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kineta, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies for cancer patients. Its pipeline includes immuno-suppression: aVISTA mAb and exhausted T-cells: aCD27 agonist mAb. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Mercer Island, WA.

BOSTON, Dec. 22, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections at its reconvened special meeting of stockholders held at 9:00 a.m. Eastern Time on December 22,...

Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio

Leading institutional investors commit $33.6 million through a common stock private investment in public equity (“PIPE”) led by Fidelity Management & Research Company, LLC and Invus

Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis

BOSTON, Nov. 16, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2020. In August 2020, Proteostasis and Yumanity Therapeutics, Inc. ("Yumanity"),...

Proteostasis Therapeutics Reports Third Quarter 2020 Financial Results

Proteostasis Therapeutics (PTI) has been struggling lately, but the selling pressure may be coming to an end soon.

Proteostasis Therapeutics (PTI) Sees Hammer Chart Pattern: Time to Buy?

Atmos Energy

Cigna

Otter Tail

TreeHouse Foods

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Bet on Rising P/E With These 5 Top Stocks

PHILADELPHIA, Sept. 14, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Proteostasis Therapeutics, Inc.

Kaskela Law LLC Announces Investigation of Proteostasis Therapeutics, Inc. (PTI) and Encourages PTI Shareholders to Contact the Firm

A Boston-area biotech has found a nifty way to go public--by sneaking in the back door.

Yumanity Therapeutics to Join Public Markets Via Merger

NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Proteostasis Therapeutics, Inc.

STOCKHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Proteostasis Therapeutics, Inc. - PTI

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

PROTEOSTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Proteostasis Therapeutics, Inc. - PTI

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Proteostasis Therapeutics, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Proteostasis Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--Rowley Law PLLC is investigating potential securities law violations by Proteostasis Therapeutics, Inc. (NASDAQ: PTI) and its board of directors concerning the proposed acquisition of the company by Yumanity Therapeutics.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Proteostasis Therapeutics, Inc.

Wilmington, Delaware--(Newsfile Corp. - August 25, 2020) - Rigrodsky & Long, P.A.

PROTEOSTASIS THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A.

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Proteostasis Therapeutics, Inc.

PROTEOSTASIS MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether The Merger of Proteostasis Therapeutics, Inc. is Fair to Shareholders; Investors are Encouraged to Contact The Firm

New York, New York--(Newsfile Corp. - August 24, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Proteostasis Therapeutics, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Proteostasis Therapeutics, Inc. and Yumanity Therapeutics, Inc.

BOSTON, Aug. 24, 2020 /PRNewswire/ -- Yumanity Therapeutics and Proteostasis Therapeutics, Inc.

Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement

Proteostasis (PTI) delivered earnings and revenue surprises of 19.05% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Proteostasis Therapeutics (PTI) Reports Q2 Loss, Misses Revenue Estimates

Avinger

Bioline RX

Vaccinex Inc

Viveve Medical

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Bet on Rising Price-to-Earnings With 5 Top Stocks

BOSTON, June 5, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that, due to public health and safety...

Proteostasis Therapeutics Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

BOSTON, June 1, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced results from in vitro studies evaluating the...

Proteostasis Therapeutics Announces In Vitro Data for PTI-129 as Potential Treatment Candidate for COVID-19

Proteostasis Therapeutics: A Clinical Stage Company That's Worth The Risk

Proteostasis (PTI) delivered earnings and revenue surprises of 17.39% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Proteostasis Therapeutics (PTI) Reports Q1 Loss, Lags Revenue Estimates

BOSTON, May 15, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced financial results for the first quarter...

Proteostasis Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

FireEye

JAKKS Pacific

Energous

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

5 Top Stocks With Rising P/E to Bet On

Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Proteostasis Therapeutics (PTI) Report Negative Q1 Earnings? What You Should Know

We expect Proteostasis Therapeutics (PTI) to provide updates on its pipeline when its releases fourth-quarter 2019 results.

News for Proteostasis Therapeutics Stock (PTI)